Quick Answer
Axsome Therapeutics, Inc. reported R&D Expense of $183.28 million for fiscal year 2025.
Axsome Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $183.28M | -2.0% |
| 2024 | $187.08M | +91.0% |
| 2023 | $97.94M | +69.0% |
| 2022 | $57.95M | -0.2% |
| 2021 | $58.06M | -17.3% |
| 2020 | $70.24M | +30.9% |
| 2019 | $53.65M | +128.3% |
| 2018 | $23.50M | +17.7% |
| 2017 | $19.96M | -5.9% |
| 2016 | $21.20M | +212.8% |
| 2015 | $6.78M | +58.4% |
| 2014 | $4.28M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.16M | -11.5% | -18.9% |
| June 30, 2025 | $49.54M | -0.6% | +10.6% |
| March 31, 2025 | $44.78M | +21.6% | -1.3% |
| September 30, 2024 | $45.39M | +57.8% | -9.0% |
| June 30, 2024 | $49.85M | +142.2% | +35.4% |
| March 31, 2024 | $36.83M | +107.0% | +28.0% |
| September 30, 2023 | $28.77M | +93.4% | +39.8% |
| June 30, 2023 | $20.58M | +30.3% | +15.7% |
- Axsome Therapeutics, Inc. showed a decrease of -2.0% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Axsome Therapeutics, Inc.’s r&d expense has grown by 4183.0% (from $4.28 million to $183.28 million).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: